

**S10 Table.** Real-world clinical outcomes of consolidative durvalumab following definitive concurrent chemoradiotherapy for non–small cell lung cancer

First author (publication, year)	Study design	No. of patients (entire /with durvalumab)	Percentage of patients with PD-L1 (+)	Radiation dose (Gy)	Median follow-up period (mo)	Progression-free survival			Overall survival		
						Median (mo)	1 yr (%)	2 yr (%)	Median (mo)	1 yr (%)	2 yr (%)
OURS	Single center	171/89	69.7	60 (50-73)	26.7	20.9	55.8	46.3	NR	92.1	77.5
Girard (2023) [1] <sup>a)</sup>	Multi center	1,399/1,399	72.4	66 (8-93)	23.5	21.7	62.2	48.2	NR	NA	71.2
Park (2023) [2] <sup>a)</sup>	Multi center	157/157	79.0	54-66	19.1	25.9	59.4	51.8	NR	87.8	71.0
Guberina (2022) [3]	Multi center	160/39	46.8	54-66	25.8	NR	77.0	65.0	NR	90.0	78.0
Yamamoto (2022) [4]	Single center	68/36	45.6	60 or 66	14.3	22.0	68.0	46.0	NR	91.0	78.0
Jung (2020) [5]	Single center	61/21	42.8	54-66	N/A	NR	59.0	(–)	NA	NA	NA
Miura (2020) [6]	Single center	41/41	49.0	54 or 60	9.03	14.1	NA	NA	15.4	NA	NA
Tsukita (2021) [7]	Multi center	107/87	56.1	60 (54-75)	14.3	NR	70.6	(–)	NA	NA	NA
Desilets (2021) [8]	Multi center	268/147	63.3	NA	15.8	NA	NA	NA	NR	92.5	(–)
Taugner (2021) [9]	Single center	26/26	100.0	At least 60 (92%)	20.6	NR	62.0	52.0	NR	100	74.0

NA, not available; NR, not-reached; PD-L1, programmed cell death ligand 1. <sup>a)</sup>PACIFIC-R and PACIFIC-KR, multicenter, retrospective, observational studies conducted on patients who participated in the early access program for durvalumab.

## References

1. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. *J Thorac Oncol.* 2023;18:181-93.
2. Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG, et al. Korean real-world data on patients with unresectable stage III NSCLC treated with durvalumab after chemoradiotherapy: PACIFIC-KR. *J Thorac Oncol.* 2023;18:1042-54.
3. Guberina M, Guberina N, Pottgen C, Gauler T, Richlitzki C, Metzenmacher M, et al. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. *Immunotherapy.* 2022;14:927-44.
4. Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, et al. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. *BMC Cancer.* 2022;22:364.
5. Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. *Lung Cancer.* 2020;146:23-9.
6. Miura Y, Mouri A, Kaira K, Yamaguchi O, Shiono A, Hashimoto K, et al. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. *Thorac Cancer.* 2020;11:1280-7.
7. Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H, et al. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. *Radiother Oncol.* 2021;160:266-72.
8. Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer.* 2021;142:83-91.
9. Taugner J, Kasmann L, Eze C, Ruhle A, Tufman A, Reinmuth N, et al. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. *Invest New Drugs.* 2021;39:1189-96.